Abstract: The invention relates to formulations comprising: (i) a first active material; (ii) a second active material; and (iii) a metal-coordination complex, wherein the first active material and the second active material have at least one surface property which is different, one from the other. Such formulations are more homogenous than those formed without the metal-coordination complex and can be used to form composite materials, such as those forming part of a conductive interface, having advantageous properties and providing for improvement in functionality of the conductive interface.

Abstract: The present invention describes the use of metal-ligand complexes within the active material of an electrode to provide for improvement in operation as well as to mitigate the cyclic stresses of swelling of the active material during charging and discharging operations and to provide resistance to dissolution of electrode active materials.

Abstract: The invention relates to formulations comprising: (i) a first active material; (ii) a second active material; and (iii) a metal-coordination complex, wherein the first active material and the second active material have at least one surface property which is different, one from the other. Such formulations are more homogenous than those formed without the metal-coordination complex and can be used to form composite materials, such as those forming part of a conductive interface, having advantageous properties and providing for improvement in functionality of the conductive interface.

Abstract: The present invention describes the use of metal-ligand complexes within the active material of an electrode to provide for improvement in operation as well as to mitigate the cyclic stresses of swelling of the active material during charging and discharging operations and to provide resistance to dissolution of electrode active materials.

Abstract: A battery electrode comprising a porous polymeric material having at least a coating of an active material applied thereto. The battery electrode may be a 3-dimensional electrode.

Abstract: A tube welding rod resistant to high stress abrasion is used for hard facing of an abrasion-resistant layer, and comprises a welded tube and a filler filling the welded tube. The filler comprises, in weight percentages, 65-90% of spherical sintered tungsten carbide particles, 5-30% of spherical cast tungsten carbide particles, 0-15% of mechanically ground cast tungsten carbide particles, 2-6% of alloy power, and 0.2-1% of an organic binder. The used of the mixed spherical sintered tungsten carbide particles and the spherical cast tungsten carbide particles improves the abrasion resistance performance of the hard-faced layer in the high stress working condition, improves the overall abrasion resistance of the abrasion-resistant hard-faced layer formed by the welding rod, and is suitable for surface hardening of bits.

Abstract: An electrode material for a battery or for a capacitor, supercapacitor or a pseudo capacitor comprises a porous substrate coated with a coating comprising a conducting material and an active material, wherein the thickness of the coating is less than 1 micrometre and the volume fraction of active material is greater than 5%. In another aspect, the electrode material comprises a metallic network structure and an active material connected to the metallic structure, wherein the calculated volume fraction of active material is greater than 5%, and the surface area of the material is greater than 5 m2/g.

Abstract: A method for depositing a metal containing material onto a porous substrate, the method comprises forming a seed coating on the substrate, wherein the seed coating at least partially covers the substrate, the seed coating being substantially free of precious metal and applying a metal containing material to the seed coating, wherein the surface area of the substrate is greater than 0.02 m2/cc, as determined prior to coating the substrate. Non-porous substrates may also be coated using a similar process.

Abstract: A tube welding rod resistant to high stress abrasion is used for hard facing of an abrasion-resistant layer, and comprises a welded tube and a filler filling the welded tube. The filler comprises, in weight percentages, 65-90% of spherical sintered tungsten carbide particles, 5-30% of spherical cast tungsten carbide particles, 0-15% of mechanically ground cast tungsten carbide particles, 2-6% of alloy power, and 0.2-1% of an organic binder. The used of the mixed spherical sintered tungsten carbide particles and the spherical cast tungsten carbide particles improves the abrasion resistance performance of the hard-faced layer in the high stress working condition, improves the overall abrasion resistance of the abrasion-resistant hard-faced layer formed by the welding rod, and is suitable for surface hardening of bits.

Abstract: A tube welding rod resistant to low stress abrasion comprises a welded tube and a filler filling the welded tube. Components of the filler comprise macrocrystalline tungsten carbide particles, cast tungsten carbide particles and/or spherical cast tungsten carbide particles undergone surface carburization treatment, mechanically ground cast tungsten carbide particles, alloy powder, and an organic binder. The weight percentages of the components are: the macrocrystalline tungsten carbide particles being 10-50%, the cast tungsten carbide particles and/or spherical cast tungsten carbide particles undergone surface carburization treatment being 43-85%, the mechanically ground cast tungsten carbide particles being 0-20%, the alloy powder being 2-6%, and the organic binder being 0.2-1%. The welding rod improves the abrasion resistance performance of the hard-faced layer in the low stress working condition, and is particularly suitable for surface hardening of cone rolling bits and diamond bits.

Abstract: A battery electrode comprising a porous polymeric material having at least a coating of an active material applied thereto. The battery electrode may be a 3-dimensional electrode.

Abstract: An enzyme linked immunosorbent assay (ELISA) method and kit for detecting soluble programmed cell death 5 (PDCD5) protein are provided. The method includes the following steps: (1) contacting a sample to be tested with a solid carrier loaded with a first antibody of PDCD5 protein; (2) adding a second antibody of PDCD5 protein, which is capable to binding to a detecting label; (3) adding the detecting label and detecting the bound detecting label. The soluble PDCD5 in a biological sample from a mammal comprising human can be detected by the ELISA method and kit. The method and kit can be used for detecting the level of PDCD5 protein in plasma, serum, urine, cerebrospinal fluid and synovial fluid so that an auxiliary detection method, for diagnosis of autoimmune disease, inflammation (such as hepatitis), and tumor etc., determination of disease course, observation of therapeutic effect and prognosis and medical guidance, is provided.

Abstract: The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.